Clinical Trials
42 trialsNCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04784715 2026-05-22
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca
Phase 3 Active not recruiting
NCT04622319 2026-05-15
DESTINY-Breast05
Daiichi Sankyo
Phase 3 Active not recruiting
NCT05374512 2026-05-15
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
AstraZeneca
Phase 3 Active not recruiting
NCT02032823 2026-05-06
OlympiA
AstraZeneca
Phase 3 Active not recruiting
NCT05104866 2026-05-05
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
AstraZeneca
Phase 3 Active not recruiting
NCT04305496 2026-04-30
CAPItello-291
AstraZeneca
Phase 3 Active not recruiting
NCT02576431 2026-04-28
NAVIGATE
Bayer
Phase 2 Completed
NCT03155997 2026-04-24
monarchE
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03157128 2026-04-16
LIBRETTO-001
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT03701334 2026-04-01
NATALEE
Novartis
Phase 3 Active not recruiting
NCT05654623 2026-03-18
VERITAC-2
Pfizer
Phase 3 Active not recruiting
NCT04191499 2026-03-17
INAVO120
Hoffmann-La Roche
Phase 2/3 Active not recruiting
NCT04494425 2026-03-04
DB-06
AstraZeneca
Phase 3 Active not recruiting
NCT05113251 2026-02-23
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT02000622 2026-02-13
OlympiAD
AstraZeneca
Phase 3 Completed
NCT03899792 2026-01-06
LIBRETTO-121
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT01358877 2025-11-28
APHINITY
Hoffmann-La Roche
Phase 3 Completed
NCT03036488 2025-10-29
MK-3475-522
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03529110 2025-10-21
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Daiichi Sankyo
Phase 3 Active not recruiting
NCT03734029 2025-10-06
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Daiichi Sankyo
Phase 3 Active not recruiting
NCT03778931 2025-09-15
EMERALD
Stemline Therapeutics, Inc.
Phase 3 Completed
NCT01772472 2025-07-22
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Hoffmann-La Roche
Phase 3 Completed
NCT04975308 2025-07-11
EMBER-3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03248492 2025-06-26
DESTINY-Breast01
Daiichi Sankyo
Phase 2 Terminated
NCT02052778 2025-03-27
A Study of TAS-120 in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
Phase 1/2 Completed
NCT02437318 2025-02-13
SOLAR-1
Novartis
Phase 3 Completed
NCT02819518 2024-11-27
KEYNOTE-355
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03901339 2024-10-21
TROPiCS-02
Gilead Sciences
Phase 3 Completed
NCT03493854 2024-06-26
FeDeriCa
Hoffmann-La Roche
Phase 3 Completed
NCT02278120 2024-03-12
MONALEESA-7
Novartis
Phase 3 Completed
NCT02422615 2023-11-30
MONALEESA-3
Novartis
Phase 3 Completed
NCT02614794 2023-08-14
HER2CLIMB
Seagen Inc.
Phase 2 Completed
NCT02425891 2022-07-19
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
Hoffmann-La Roche
Phase 3 Completed
NCT02574455 2022-06-15
ASCENT
Gilead Sciences
Phase 3 Completed
NCT01945775 2022-01-20
EMBRACA
Pfizer
Phase 3 Completed
NCT01631552 2021-08-12
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gilead Sciences
Phase 1/2 Completed
NCT00878709 2021-06-11
ExteNET
Puma Biotechnology, Inc.
Phase 3 Completed
NCT01808573 2021-06-11
NALA
Puma Biotechnology, Inc.
Phase 3 Completed
NCT01566721 2021-04-27
SafeHER
Hoffmann-La Roche
Phase 3 Completed
NCT00950300 2018-01-23
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
Hoffmann-La Roche
Phase 3 Completed